Day One

Break the ice before the science begins. Join your table for a light hearted, TRP-themed networking activity designed to get conversations flowing, strengthen connections and maximize your networking opportunities throughout the summit.

• Explore the rationale for selecting novel targets with therapeutic potential beyond established RLT targets
• Apply lessons learned from advancing PSMA and FAP programs into clinical development to inform target selection and candidate optimization
• Leverage insights from PSMA and FAP around affinity, internalization, tumor uptake and retention to guide the design of next-generation candidates

• Challenging static receptor-density thresholds to prevent promising therapeutic targets being ruled out too early
• Understanding internalization & receptor replenishment to determine how lowerdensity targets can still deliver sufficient radiation to the tumor
• Redefining “good enough” target expression to identify a broader range of viable targets for RLT development

Novel Target

• Explore LFA-1 on leukocytes as an emerging target to move beyond conventional tumor-cell receptor expression
• Harness innate immune biology and leukocyte activity within the tumor environment to identify new opportunities for targeted imaging and therapy
• Translate LFA-1-targeted ligands from imaging into therapeutic applications, leveraging early clinical validation to inform next-generation development

Novel Target

A prime opportunity to make the most of in-person networking and forge new connections with an expanding community of experts in the radiopharmaceutical field. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the Summit.

• Targeting abundant ECM components beyond tumor-cell receptors to reduce dependence on variable or low receptor expression
• Exploiting tumor-specific ECM accumulation & accessibility to deliver and retain greater radioactive retention within the tumor
• Identifying conserved ECM targets across tumor types to unlock RLT opportunities across primary & metastatic disease

Novel Target

• Validating promising academic biology in increasingly translational models to establish whether the target is robust enough for drug development
• Identifying the critical experiments that increased or challenged confidence to determine when continued investment was justified
• Bridging academic discovery & industry validation requirements to build an evidence package capable of progressing a novel target towards the clinic

Novel Target

• Validating tumor-to-healthy expression, prevalence, & heterogeneity to confirm the target is sufficiently selective and consistent to progress
• Assessing accessibility, internalization, replenishment, & density to prove the target can support meaningful radionuclide delivery
• Defining the minimum in vitro, in vivo & imaging evidence to make earlier, higherconfidence target go/no-go decisions

• Use brain metastases as a clinical case study to understand target accessibility, engagement, and biodistribution within the challenging brain environment
• Leverage clinical imaging to determine whether a targeting agent can reach and sufficiently accumulate within brain lesions
• Translate lessons from imaging into target-validation criteria for therapeutic development, while accounting for the different requirements of imaging and RLT

Novel Target

• Designing covalent radiohalogen therapeutics with matched diagnostic–therapeutic pairs to improve predictive biodistribution and translational confidence
• Overcoming traditional limitations of chelated radiometals by reducing off-target accumulation and enabling blood-brain barrier penetration
• Presenting preclinical imaging and efficacy data showing remarkable tumor control and favorable safety profiles across small molecule and bioligand-tagged platforms

• Understand how target biology and molecular format should inform early radiopharmaceutical design decisions
• Optimize Affibody-based targeting agents, chelators and radionuclide selection to improve biodistribution and tumor targeting
• Apply successes and failures from candidate development to identify which design characteristics are most likely to translate

• Explore the preclinical development of a DLL3-targeted radiotherapeutic from candidate design through efficacy evaluation
• Assess how biodistribution, tumor uptake & retention inform optimization of radiotherapeutic performance
• Leverage preclinical findings to guide candidate selection & progression towards clinical development

Novel Target

A prime opportunity to make the most of in-person networking and forge new connections with an expanding community of experts in the radiopharmaceutical field. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the Summit.

To submit a poster please reach out to poster@hansonwade.com

• Assessing tumor size, architecture & target heterogeneity to determine whether short-range alpha or longer-range beta irradiation provides better disease coverage
• Leveraging beta crossfire or high-LET alpha irradiation to overcome differences in target density & spatial distribution
• Matching radionuclide half-life & dose rate to vector PK and tumor residence to ensure radiation is delivered while the targeting agent remains at the tumor

• Translate novel At-211 compounds from discovery through preclinical development, examining the studies required to build confidence ahead of clinical translation
• Navigate preclinical toxicity & translational considerations when progressing an At- 211 program towards FIH evaluation
• Share lessons from investigator-initiated Phase I development to identify what early-stage RLT developers should consider when designing the next generation of alpha-emitting therapeutics

Novel Target